Form 4: CalciMedica Director Glicklich Receives Stock Options

CalciMedica Director Alan Glicklich was granted 937 stock options with an exercise price of $3.26, vesting monthly starting October 1, 2025, under a 10b5-1 plan.

Summary

• Alan Glicklich, a Director of CalciMedica, Inc. (CALC), was granted 937 Director Stock Options.
• The transaction date for the grant was October 13, 2025.
• The exercise price for these options is $3.26 per share.
• The options begin vesting on October 1, 2025, with 1/3rd of the shares vesting in equal monthly installments thereafter.
• The options have an expiration date of October 12, 2035.
• The transaction was made pursuant to a Rule 10b5-1 plan.
• Following this transaction, Mr. Glicklich beneficially owns 937 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive. The grant of stock options to a director is a routine event but positively aligns the director's interests with long-term shareholder value. No negative implications are present.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The establishment of a Rule 10b5-1 plan indicates a pre-planned transaction, reducing concerns about insider trading based on material non-public information.

Risks

• The value of the stock options is contingent on the future performance of CalciMedica's stock price exceeding the exercise price of $3.26.
• There is no guarantee that the stock price will rise above the exercise price, potentially rendering the options worthless.

Future Outlook

The vesting schedule extending into the future indicates a long-term incentive structure for the director, aligning their interests with the company's sustained performance.

Industry Context

Granting stock options to directors is a common practice in publicly traded companies, particularly in the biotechnology or pharmaceutical sector where long-term value creation is paramount, to attract and retain experienced board members and align their interests with shareholders.

Comparison to Industry Standards

• Equity compensation for directors, such as stock options, is a standard practice across industries, including biotechnology, to incentivize long-term performance and align interests.
• The specific number of options (937) and exercise price ($3.26) would need to be compared against CalciMedica's peer group (e.g., other small-cap biotech firms) to assess if it's within typical ranges for director compensation, though this filing alone does not provide enough context for a detailed peer comparison.
• The use of a Rule 10b5-1 plan is a best practice for insider transactions, demonstrating a commitment to ethical trading and compliance with SEC regulations, consistent with corporate governance standards.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director (Alan Glicklich) constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Management: The director receives equity compensation, incentivizing continued service and strategic contributions.

Next Steps

• The stock options will begin vesting on October 1, 2025, over a period of time.
• The director may choose to exercise these options at any point between their vesting date and the expiration date of October 12, 2035, assuming the stock price is favorable.

Key Dates

Recommendation

This Form 4 filing reports a routine compensation event for a director, which is a standard practice to align interests. It does not contain any new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in an investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on the company's fundamentals rather than this specific insider transaction.

Keywords

CalciMedica, CALC, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Alan Glicklich, 10b5-1 Plan